Acar J F, Goldstein F W
Laboratoire de Microbiologie Médicale, Fondation Hôpital Saint-Joseph, Paris, France.
Clin Infect Dis. 1997 Jan;24 Suppl 1:S67-73. doi: 10.1093/clinids/24.supplement_1.s67.
The emergence of resistance to fluoroquinolones in virtually all species of bacteria was recognized soon after the introduction of these compounds for clinical use more than 10 years ago. Various resistance mechanisms, often interdependent, may explain different levels of resistance. Epidemiological factors, local antibiotic policies, patients' characteristics, origin of the strains, and geographic location are among the factors contributing to highly variable resistance rates. During the last several years, resistance to fluoroquinolones has remained very high among methicillin-resistant Staphylococcus aureus strains and in intensive care unit patients, and it has increased among nosocomial isolates of Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa. More worrisome are recent reports of an overall increase in resistance to fluoroquinolones among bacteria responsible for community-acquired infections, such as Escherichia coli, Salmonella species, Campylobacter species and Neisseria gonorrhoeae.
在10多年前氟喹诺酮类化合物被引入临床使用后不久,几乎所有细菌种类中对氟喹诺酮类药物的耐药性就出现了。各种耐药机制往往相互依存,可能解释了不同程度的耐药性。流行病学因素、当地抗生素政策、患者特征、菌株来源和地理位置等都是导致耐药率高度可变的因素。在过去几年中,耐甲氧西林金黄色葡萄球菌菌株和重症监护病房患者中对氟喹诺酮类药物的耐药性一直很高,而在肺炎克雷伯菌、粘质沙雷氏菌和铜绿假单胞菌的医院分离株中耐药性有所增加。更令人担忧的是最近的报告称,在引起社区获得性感染的细菌中,如大肠杆菌、沙门氏菌属、弯曲杆菌属和淋病奈瑟菌,对氟喹诺酮类药物的耐药性总体有所增加。